atezolizumab
Tecentriq (atezolizumab) is a PD-L1 checkpoint inhibitor from Genentech. By releasing the brake that tumours put on immune T cells, it lets the immune system attack cancer, and is used in selected lung cancers, urothelial carcinoma and other settings defined by PD-L1 testing.
This page is based on FDA prescribing information and the EMA medicine record for atezolizumab, cross-checked with DailyMed and the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
A tumour often waves a molecular white flag, PD-L1, that tells passing immune soldiers, "do not shoot." The soldiers lower their weapons and walk past. Atezolizumab covers the white flag, so the soldiers see the tumour for what it is and open fire.
In simple terms
T cells are immune cells that can destroy cancer, but tumours protect themselves by displaying PD-L1, a protein that binds the PD-1 switch on T cells and turns them off. Atezolizumab is an antibody that binds PD-L1 on tumour and immune cells, preventing that handshake. Freed from the brake, T cells recognise and kill cancer cells again.
In depth
Atezolizumab is a humanised, Fc-engineered IgG1 monoclonal antibody that binds PD-L1 (CD274), blocking its interaction with PD-1 and B7.1 on T cells. This releases PD-1-mediated suppression of T-cell activation, restoring proliferation, cytokine production and cytotoxic activity against tumour cells. The Fc region is modified to minimise antibody-dependent cellular cytotoxicity against PD-L1-expressing immune cells, preserving antigen presentation while lifting the checkpoint brake.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How atezolizumab, an Fc-engineered antibody, blocks PD-L1
- T cells are immune cells that can destroy cancer, but tumours protect themselves by displaying PD-L1, a protein that binds the PD-1 switch on T cells and turns them off.
- Atezolizumab is a humanised, Fc-engineered IgG1 monoclonal antibody that binds PD-L1 (CD274), blocking its interaction with PD-1 and B7.1 on T cells.
- This releases PD-1-mediated suppression of T-cell activation, restoring proliferation, cytokine production and cytotoxic activity against tumour cells.
- The Fc region is modified to minimise antibody-dependent cellular cytotoxicity against PD-L1-expressing immune cells, preserving antigen presentation while lifting the checkpoint brake.
Target: Programmed death-ligand 1 (PD-L1)
A surface protein that many tumours display to switch off attacking T cells through the PD-1 checkpoint; blocking it reawakens the anti-tumour immune response.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- As adjuvant treatment following resection and platinum-based chemotherapy for adults with stage II to IIIA non-small cell lung cancer whose tumors have PD-L1 expression on 1 percent or more of tumor cells, as determined by an FDA-authorized test
- For the first-line treatment of adults with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations
- With carboplatin and etoposide, for the first-line treatment of adults with extensive-stage small cell lung cancer
Approved uses in European Union
EMA- As monotherapy for adults with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy, or who are considered cisplatin ineligible and whose tumours have a PD-L1 expression of 5 percent or higher
- As monotherapy as adjuvant treatment following complete resection and platinum-based chemotherapy for adults with early-stage non-small cell lung cancer with high risk of recurrence
Official sources
The statements on this page trace back to these records.
- Tecentriq (atezolizumab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- DailyMed: Tecentriq (atezolizumab) label
DailyMed, U.S. National Library of Medicine
- U.S. Food and Drug Administration: atezolizumab prescribing information
U.S. Food and Drug Administration
- National Cancer Institute: atezolizumab
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.